Your web browser is out of date.

For your security and improved experience online, please update your browser.

Diabetes on the Net is intended for healthcare professionals

This promotional webinar was initiated and fully funded by AstraZeneca. The content has been reviewed and approved by the sponsoring company and the speakers prior to broadcast. Editorial support for this webinar was provided by OmniaMed Communications.

Forxiga® (dapagliflozin) for managing chronic heart failure (HFrEF) in people with or without type 2 diabetes: New NICE guidance

Taking place on:

Next event starting shortly. Already registered?

About the webinar

Forxiga® (dapagliflozin) for managing chronic heart failure (HFrEF) in people with or without type 2 diabetes: New NICE guidance

Heart failure (HF) is responsible for a significant number of hospitalisations and is a leading cause of death in people with type 2 diabetes.1-4 Clinical trials have demonstrated that the SGLT2 inhibitor Forxiga reduces the risk of hospitalisation for HF,3,4 and it is now indicated in people with chronic heart failure with reduced ejection fraction (HFrEF) with or without type 2 diabetes.1

 

Join us for a live webinar on 31 March 2021 at 13:00 chaired by Yassir Javaid, and an expert faculty consisting of Pam Brown, Jane Diggle, Naresh Kanumilli and Nicola Milne. Alongside presenting the clinical trial data for dapagliflozin in people with HF, the practicalities of initiating dapagliflozin in this population will also be discussed. Throughout the webinar you will have the opportunity to submit your questions for a live question and answer session with the speakers immediately after the broadcast

What does this webinar offer?

About the webinar

15 minutes

Forxiga® (dapagliflozin) for managing chronic heart failure (HFrEF) in people with or without type 2 diabetes: New NICE guidance

30 minutes

Expert panel discussion:

Practical advice on identification of people with or without type 2 diabetes who have HF, and clinical considerations for prescribing Forxiga (dapagliflozin)

15 minutes

Live Q&A session

Speakers

Dr-Yassir-Javaid.jpg

Yassir Javaid

GPwSI in Cardiology, Northampton

Pam_CRL.png

Pam Brown

GP in Swansea, Wales, and Welsh representative on the PCDS Committee

Jane-Diggle.jpg

Jane Diggle

Practice Nurse with Specialist Interest in Diabetes, West Yorkshire

Naresh Kanumilli

Naresh Kanumilli

Community Diabetes Consultant, Manchester

Nicola-Milne_1.jpg

Nicola Milne

Community DSN, Manchester

Forxiga® (dapagliflozin) for managing chronic heart failure (HFrEF) in people with or without type 2 diabetes: New NICE guidance

Taking place on:

This promotional webinar was initiated and fully funded by AstraZeneca. The content has been reviewed and approved by the sponsoring company and the speakers prior to broadcast. Editorial support for this webinar was provided by OmniaMed Communications.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to AstraZeneca by visiting https://aereporting.astrazeneca.com or by calling 0800 783 0033.

References

  1. Forxiga 10 mg film-coated tablets. Summary of Product Characteristics. November 2020
  2. Bailey CJ, et al. Lancet. 2010;375:2223-2233.
  3. Wiviott SD, et al. N Engl J Med 2019; 380:347-357.
  4. McMurray JJV, et al. N Engl J Med. 2019;381:1995-2008.

GB 27621 | March 2021

Forxiga® (dapagliflozin) for managing chronic heart failure (HFrEF) in people with or without type 2 diabetes: New NICE guidance

Practical experiences from running an adeno-associated virus gene therapy trials: The Principal Investigator’s perspective

XX September 2020

Complete the registration form

XX Month 2020

Complete the registration form

We use cookies to ensure that we give you the best experience on our website. Some may have been set already. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies. If you have any concerns about this, please click here to find out more.

* Mandatory Field
Your data is being collected by OmniaMed Communications on behalf of Novo Nordisk solely for the purpose of processing your registration. Your details will not be shared with any parties other than OmniaMed Communications and Novo Nordisk.